[1] Chen Z. Cell therapy for Parkinson's disease:new hope from reprogramming technologies[J]. Aging Dis, 2015, 6(6):499-503. [2] Sheng C, Zheng Q, Wu J,et al. Generation of dopaminergic neurons directly from mouse fibroblasts and fibroblast-derived neural progenitors[J].Cell Res,2012,22(4):769-772. [3] Tang X, Wang S, Bai Y, et al. Conversion of adult human peripheral blood mononuclear cells into neural stem cell by using episomal vectors[J]. Stem Cell Res, 2016,16(2):236-242. [4] Yuan Y, Tang X, Bai Y F, et al. Dopaminergic precursors differentiated from human blood-derived induced neural stem cells improve symptoms of a mouse Parkinson's disease model[J]. Theranostics,2018, 8(17):4679-4694. [5] Chen Z,Palmer T D. Differential roles of TNFR1 and TNFR2 signaling in adult hippocampal neurogenesis[J]. Brain Behav Immun,2013, 30:45-53. [6] Wang S, Zou C, Fu L, et al. Autologous iPSC-derived dopamine neuron transplantation in a nonhuman primate Parkinson's disease model[J]. Cell Discovery,2015,1:15012, [7] Ren Z, Wang J, Wang S,et al. Autologous transplantation of GDNF-expressing mesenchymal stem cells protects against MPTP-induced damage in cynomolgus monkeys[J]. Sci Rep, 2013, 27(3):2786. [8] Park J H, Riviere I, Gonen M, et al. Long-term follow-up of CD19 CAR therapy in acute lymphoblastic leukemia[J]. New Engl J Med, 2018,378(5):449-459. [9] Shah N N, Fry T J. Mechanisms of resistance to CAR T cell therapy[J]. Nat Rev Clin Oncol,2019,16(6):372-385. [10] Zhao Y, Liu Z, Wang X, et al. Treatment with humanized selective CD19CAR-T cells shows efficacy in highly treated b-all patients who have relapsed after receiving murine-based CD19CAR-T therapies[J]. Clin Cancer Res,2019,25(18):5595-5607. |